RESUMEN
Sixty to seventy percent of IFN-γ(-/-) NOD.H-2h4 mice given sodium iodide (NaI)-supplemented water develop a slow onset autoimmune thyroid disease, characterized by thyrocyte epithelial cell (TEC) hyperplasia and proliferation (H/P). TEC H/P develops much earlier in CD28(-/-) mice and nearly 100% (both sexes) have severe TEC H/P at 4 mo of age. Without NaI supplementation, 50% of 5- to 6-mo-old CD28(-/-)IFN-γ(-/-) mice develop severe TEC H/P, and 2-3 wk of NaI is sufficient for optimal development of severe TEC H/P. Mice with severe TEC H/P are hypothyroid, and normalization of serum thyroxine levels does not reduce TEC H/P. Activated CD4(+) T cells are sufficient to transfer TEC H/P to SCID recipients. Thyroids of mice with TEC H/P have infiltrating T cells and expanded numbers of proliferating thyrocytes that highly express CD40. CD40 facilitates, but is not required for, development of severe TEC H/P, as CD40(-/-)IFN-γ(-/-)CD28(-/-) mice develop severe TEC H/P. Accelerated development of TEC H/P in IFN-γ(-/-)CD28(-/-) mice is a result of reduced regulatory T cell (Treg) numbers, as CD28(-/-) mice have significantly fewer Tregs, and transfer of CD28(+) Tregs inhibits TEC H/P. Essentially all female IFN-γ(-/-)CD28(-/-) NOD.H-2h4 mice have substantial lymphocytic infiltration of salivary glands and reduced salivary flow by 6 mo of age, thereby providing an excellent new model of autoimmune exocrinopathy of the salivary gland. This is one of very few models where autoimmune thyroid disease and hypothyroidism develop in most mice by 4 mo of age. This model will be useful for studying the effects of hypothyroidism on multiple organ systems.
Asunto(s)
Enfermedades Autoinmunes/etiología , Modelos Animales de Enfermedad , Hipotiroidismo/etiología , Enfermedades de las Glándulas Salivales/etiología , Enfermedades de la Tiroides/etiología , Animales , Antígenos CD28/fisiología , Antígenos CD40/fisiología , Células Cultivadas , Células Epiteliales/patología , Hiperplasia , Interferón gamma/fisiología , Yodo/farmacología , Ratones , Ratones Endogámicos C57BL , Linfocitos T/fisiología , Glándula Tiroides/patología , Tiroxina/sangreRESUMEN
CD40 is expressed on cells of the immune system and in some tissues that are targets for autoimmune-mediated damage. It is not known if CD40 expression in target tissues plays a role in the pathology of autoimmune diseases. This study shows that agonistic anti-CD40 induces strong and sustained proliferation of thyroid epithelial cells (TECs), or thyrocytes, in IFN-γ(-/-) autoimmune-prone NOD and NOD.H-2h4 mice. TEC proliferation is accompanied by greatly increased expression of CD40 on TECs, development of fibrosis and hypothyroidism, and increased expression of proinflammatory molecules in thyroids. Bone marrow chimera experiments indicate that TEC expression of CD40 is required for anti-CD40-induced TEC proliferation, but lymphoid cells do not have to express CD40. TEC proliferation is reduced in wild-type mice given anti-CD40, presumably because they produce IFN-γ, which inhibits TEC proliferation. CD40 also increases on TECs during development of an autoimmune thyroid disease characterized by TEC hyperproliferation that develops spontaneously in IFN-γ(-/-) NOD.H-2h4 mice. TEC hyperproliferation development is accelerated in mice given agonistic anti-CD40. These studies provide new information regarding the role of target tissue expression of CD40 in development of autoimmunity and suggest that use of agonistic anti-CD40 for tumor therapy could result in autoimmune disease.
Asunto(s)
Anticuerpos/fisiología , Autoinmunidad , Antígenos CD40/agonistas , Antígenos CD40/inmunología , Proliferación Celular , Células Epiteliales/inmunología , Glándula Tiroides/inmunología , Glándula Tiroides/metabolismo , Animales , Antígenos CD40/biosíntesis , Células Epiteliales/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Ratones Endogámicos DBA , Ratones Endogámicos NOD , Ratones Noqueados , Ratones SCID , Cultivo Primario de Células , Glándula Tiroides/citologíaRESUMEN
BACKGROUND: Patients undergoing hepatectomy often require packed red blood cell (PRBC) transfusion, which has been associated with worse oncologic outcomes. However, limited data exist regarding the impact of PRBC donor factors. We hypothesized that PRBC donor age impacts survival after hepatectomy for non-hepatocellular malignancies. METHODS: Patients who underwent hepatectomy for non-hepatocellular malignancy from 2005 to 2014 were retrospectively evaluated. Impact of clinicopathologic and PRBC factors on oncologic outcomes were assessed. RESULTS: Of 149 identified patients, 76 received a perioperative PRBC transfusion (median 2 units). Transfusion was associated with increased median length of stay (8 vs. 6 days; pâ¯<â¯0.01) and median operative blood loss (700 vs. 350â¯mL; pâ¯<â¯0.01) versus non-transfused, respectively. In transfused patients, receipt of PRBC from older donors compared to younger resulted in decreased RFS (0.94 vs. 2.63 years, respectively; pâ¯=â¯0.02) and OS (1.94 vs. 3.44 years, respectively; pâ¯=â¯0.6). The PRBC donor age was an independent predictor of decreased recurrence free survival on multivariate analysis (HR 2.5, pâ¯=â¯0.04). CONCLUSIONS: In patients undergoing hepatectomy for non-hepatocellular malignancies and receiving perioperative transfusion, PRBC donor age may impact survival and warrants further investigation.
Asunto(s)
Donantes de Sangre , Transfusión de Eritrocitos , Hepatectomía/efectos adversos , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/cirugía , Atención Perioperativa , Adulto , Factores de Edad , Anciano , Pérdida de Sangre Quirúrgica , Femenino , Hepatectomía/mortalidad , Humanos , Tiempo de Internación , Neoplasias Hepáticas/patología , Masculino , Persona de Mediana Edad , Tempo Operativo , Estudios Retrospectivos , Tasa de SupervivenciaRESUMEN
IFN-γ-/-NOD.H-2h4 mice develop thyroid epithelial cell hyperplasia (TEC H/P) characterised by abnormal proliferation of thyrocytes and infiltration of thyroids by CD4+ and CD8+ T cells, macrophages and dendritic cells. CD8+ T cells from mice with severe TEC H/P transfer similar lesions to SCID recipients, whereas CD4+ T cells transfer mild TEC H/P. CD4- and CD8- deficient IFN-γ-/-NOD.H-2h4 mice were generated to determine if CD4+ T cells were required for initial activation of the CD8+ T cells that transfer TEC H/P. After 6-8 months on NaI water, only 2 of 60 CD8-/- mice developed severe TEC H/P, whereas 31 of 101 CD4-/- mice developed severe TEC H/P and fibrosis comparable in severity to that of IFN-γ-/- mice. However, splenocytes from CD4-/- mice with severe TEC H/P did not effectively transfer severe TEC H/P to SCID recipients. When CD4-/- donors were given agonistic anti-CD40 mAb, most developed severe TEC H/P and their cells transferred severe TEC H/P to SCID recipients. These results indicate that agonistic anti-CD40 can provide an important signal for activation of autoreactive CD8+ T cells that transfer severe TEC H/P. Therefore, targeting or blocking CD40 could provide effective therapy for diseases involving hyperplasia and fibrosis mediated by CD8+ T cells.